Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Phase 1
18
about 6.8 years
18+
Male only
1 site in MD
What this study is about
This trial is testing the safety of delivering three shorter radiation schedules to the pelvic area and prostate. The goal is to see if this approach can safely deliver more radiation over a longer period while minimizing damage to healthy tissues.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Hypofractionated Radiation Therapy
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: HypoFx RT schedule that results in <33% acute dose-limiting toxicity with accelerated, HypoFx pelvic nodal RT
Secondary: Evaluate the duration of biochemical progression-free survival, Frequency of acute and late GI, GU, hematologic, and neurologic toxicity for each dose cohort, Patient Reported Outcomes (PROs) related to urinary and bowel function, Patient Reported Outcomes (PROs) related to urinary function
radiation
Oncology